טוען...
Roflumilast and aquaporin‐2 regulation in rat renal inner medullary collecting duct
Roflumilast is a cyclic nucleotide phosphodiesterase inhibitor that is FDA‐approved for treatment of chronic obstructive pulmonary disease. With a view toward possible use for treatment of patients with X‐linked nephrogenic diabetes insipidus (NDI) due to hemizygous mutations in the V2 vasopressin r...
שמור ב:
| הוצא לאור ב: | Physiol Rep |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5269416/ https://ncbi.nlm.nih.gov/pubmed/28108651 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14814/phy2.13121 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|